<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01815112</url>
  </required_header>
  <id_info>
    <org_study_id>PI07-PR-MEYER1</org_study_id>
    <secondary_id>2007-A01009-44</secondary_id>
    <nct_id>NCT01815112</nct_id>
  </id_info>
  <brief_title>Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging</brief_title>
  <official_title>Benefit of MRI and 18F-FDG PET Imaging in the Early Diagnosis of Alzheimer-like Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The physio-pathology of Alzheimer's disease (AD) remains unknown and there is no cure. Thus,
      the search for objective markers of preclinical first signs of cognitive impairment, is
      currently a major public health issue. Early detection of the disease is a major challenge to
      hope to slow or even stop the neurodegenerative process before the stage of dementia.

      In AD the investigators observe:

        -  A reduction in the volume of brain hippocampi associated with an alteration of the
           diffusion of water molecules in the white matter.

        -  A structural brain degeneration coupled with a decrease in cerebral glucose metabolism.

      Recent publications show that cerebrospinal fluid (CSF)flow is also altered, probably due to
      dysfunction of the choroid plexus. Hence the potential interest to study is, in addition to
      conventional imaging, the imaging of CSF dynamics and choroid plexus metabolism. In that
      aim,the investigators use two imaging modalities:

        -  Magnetic resonance imaging (MRI) is used to assess blood and CSF flow in the brain

        -  Positron emission tomography (PET) is used to assess glucose metabolism in grey/white
           matter and also in choroid plexus.

      The investigators expect that, because of choroid plexus atrophy in AD, CSF flow would be
      altered as well as glucose metabolism dynamic in choroid plexus.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administrative re-organization of the department. Referent physician left the hospital.
  </why_stopped>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dynamic FDG (fluoro-deoxyglucose) PET</measure>
    <time_frame>Day 2</time_frame>
    <description>Extraction of tissue time-activity curves ; notably in choroid plexus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aqueductal CSF flow</measure>
    <time_frame>Day 1</time_frame>
    <description>Measurement of CSF flow at the Sylvius' aqueduct level. Calculation of the corresponding stroke volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up MRI</measure>
    <time_frame>Day 365</time_frame>
    <description>MRI examination of MCI patients after one year in order to assess CSF flow differences in MCI how converted to Alzheimer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up PET</measure>
    <time_frame>Day 366</time_frame>
    <description>Dynamic FDG PET examination of MCI patients after one year in order to assess FDG dynamic evolution in MCI how converted to Alzheimer.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>Alzheimer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alzheimer patients detected via conventional clinical and neuropsychological tests. They will undergo Magnetic resonance imaging and positron emission tomography examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vascular dementia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vascular dementia patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild cognitive impairment (MCI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild cognitive impairment (MCI) patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects (MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects agreeing to undergo magnetic resonance imaging examination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects (PET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitively healthy subjects. These subjects are people addressed in the nuclear medicine department for cancer-related positron emission tomography examination. If they agree, an extended neuropsychological test will assess that they do not suffer any cognitive disorder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic resonance imaging</intervention_name>
    <description>CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.</description>
    <arm_group_label>Alzheimer</arm_group_label>
    <arm_group_label>Vascular dementia</arm_group_label>
    <arm_group_label>Mild cognitive impairment (MCI)</arm_group_label>
    <arm_group_label>Healthy subjects (MRI)</arm_group_label>
    <other_name>Flow MRI</other_name>
    <other_name>Brain MRI</other_name>
    <other_name>Diffusion weighted imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Positron emission tomography</intervention_name>
    <description>Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.</description>
    <arm_group_label>Alzheimer</arm_group_label>
    <arm_group_label>Vascular dementia</arm_group_label>
    <arm_group_label>Mild cognitive impairment (MCI)</arm_group_label>
    <arm_group_label>Healthy subjects (PET)</arm_group_label>
    <other_name>Dynamic PET imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: over 65

          -  Participants (or representatives) gave their written informed consent

          -  Dementia diagnosed according to Diagnostic and Statistical Manual of Mental Disorders
             (DSM IV) criteria

          -  For Alzheimer arm: probable Alzheimer based disease according to NINCDS-ADRDA
             (National Institute of Neurological and Communicative Disorders and Stroke and the
             Alzheimer's Disease and Related Disorders Association ) criteria

          -  For vascular dementia: diagnosis based on NINDS-AIREN (National Institute of
             Neurological Disorders and Stroke and Association Internationale pour la Recherche et
             l'Enseignement en Neurosciences) criteria

          -  For MCI: diagnosis based on Petersen index

        Exclusion Criteria:

          -  Claustrophobia

          -  Diabetes

          -  Cardiovascular disease

          -  Glycemia over 1.3 g/L

          -  Lumbar puncture within one week before MRI examination

          -  Non MR-compatible implant

          -  Suspected brain metastases

          -  No informed consent signature
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc-Etienne MEYER, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <state>Haute Normandie</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2013</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurodegenerative disease</keyword>
  <keyword>Elderly</keyword>
  <keyword>Dementia</keyword>
  <keyword>FDG-PET</keyword>
  <keyword>MRI</keyword>
  <keyword>Neuroimaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

